Cramer says it's 'highly unlikely' tariff costs will all trickle down to consumers The economic windfall from the U.S.-China trade spat won't affect U.S. consumers as much as people think, CNBC's Jim Cramer argues. The "Mad Money" host points to the action in the retail stocks to back up his theory.
'We're ahead of the pack' in the cannabinoid drug space, says CEO of synthetic drugmaker Corbus CNBC's Jim Cramer sits down with Yuval Cohen, the CEO of a company that is creating treatments derived from manmade cannabinoids for rare diseases like cystic fibrosis.
The economic windfall from the U.S.-China trade spat won't affect U.S. consumers as much as people think, CNBC's Jim Cramer argues.
The "Mad Money" host points to the action in the retail stocks to back up his theory.
CNBC's Jim Cramer sits down with Yuval Cohen, the CEO of a company that is creating treatments derived from manmade cannabinoids for rare diseases like cystic fibrosis.